{"schema_version":"secwatch.filing_event.v1","accession":"0001792044-23-000005","form_type":"8-K","ticker":"VTRS","cik":"0001792044","company_name":"Viatris Inc","filed_at":"2023-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.562220+00:00","generated_at":"2026-06-18T23:54:47.396668+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Viatris reports FY2022 revenue $16.3B, meets adjusted guidance; provides 2023 outlook","bullets":["FY2022 total revenues $16,263M; adjusted EBITDA $5,777M; free cash flow $2,547M.","2023 guidance midpoint implies revenue growth over 2022 excluding full-year biosimilars impact; reaffirms 2024 Phase 2 outlook.","Board approves 2023 dividend policy of $0.48 per share annually; Q1 dividend $0.12 per share declared.","Completed $250M in share repurchases; paid down ~$3.3B debt in 2022, $5.4B since 2021.","On track to execute planned divestitures; biosimilars transaction closed in Q4 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001792044-23-000005","json":"https://secwatch.observer/filing/0001792044-23-000005.json","markdown":"https://secwatch.observer/filing/0001792044-23-000005.md","text":"https://secwatch.observer/filing/0001792044-23-000005.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1792044/000179204423000005/0001792044-23-000005-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1792044/000179204423000005/vtrs-20230227.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T23:54:47.396668+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"08ac6e28fb68cd8d65d855ac14f88559b9965738","claim":"Viatris Inc updated its 2023 guidance (initiated).","evidence_excerpt":"Viatris Reports Strong Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Financial Guidance","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1792044/000179204423000005/0001792044-23-000005-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"2023"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"d2f1b284a00fb847d32881d3a9bf7a6c36ecd522","claim":"Viatris Inc reported the period ended December 31, 2022 results: revenue $16,263.","evidence_excerpt":"Total Revenues $16,200 - $16,700 $(86) $— $16,100 - $16,600 $16,263","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1792044/000179204423000005/0001792044-23-000005-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the period ended December 31, 2022"},{"label":"Revenue","value":"$16,263"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}